Abstract
RationaleTo evaluate efficacy and safety of adding umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), to inhaled corticosteroid (ICS)/long-acting β-agonist (LABA) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD)...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have